Table 2.

Mean CD4 change (cells/μl) after 12 months of ART, estimated by multivariable linear mixed model.

	Mean CD4 change estimated (cells/μl)	95% Confidence interval	P value
Age at baseline^a (years)			<0.0001
[16–30]	+251^b	+239; +263
[30–35] vs. [16–30]	+3	−12; +18
[35–40] vs. [16–30]	−17	−33; −2
[40–45] vs. [16–30]	−20	−37; −3
[45–50] vs. [16–30]	−34	−54; −15
[50–81] vs. [16–30]	−22	−43; −2
Baseline^a CD4 cell count			<0.0001
For 50 cells/μl lower	+19	+18; +20
Sex			<0.0001
Women vs. men	+30	+21; +39
Baseline^a clinical stage			<0.0001
A, B/I, II vs. AIDS/WHO III, IV	+17	+6; +28
Year of ART initiation			<0.0001
Prior to 2004 vs. up to 2003	−48	−64; −31
Initial ART regimen			<0.0001
PI-based vs. NNRTI-based	−36	−54; −18
Others regimen vs. NNRTI-based	−45	−60; −30

IeDEA West Africa Collaboration.

ART, antiretroviral treatment; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Baseline: initiation of ART.

For the reference group: 16–30-year-old women, initiating NNRTI regimen after 2003 at Centers for Disease Control clinical stage A, B or WHO I, II and with 180 CD4 cells/μl at baseline.